Logo

Nanogen and Jurilab Partner on Type 2 Diabetes Biomarker Discovery

May 15, 2006

NEW YORK, May 15 (GenomeWeb News) - Nanogen and Jurilab will collaborate to identify and validate new prognostic markers for type 2 diabetes, the companies said today.

 

Jurilab will use data from a genetic screening project involving an isolated population in East Finland to identify potential markers associated with predisposition to diabetes as well as resistance to developing the disease.

 

The companies will collaborate to validate the diabetes associations of these markers in populations outside Finland, including case controls in Catalonia, England, Germany, and from Ashkenazi Jews.

 

Nanogen plans to develop diagnostic tests for panels of confirmed markers, and the companies will jointly seek pharmaceutical partners to develop therapeutics based on genes determined to play a role in the disease.

Breaking News
The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.